Atara Biotherapeutics Inc
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as… Read more
Atara Biotherapeutics Inc (ATRA) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.267x
Based on the latest financial reports, Atara Biotherapeutics Inc (ATRA) has a cash flow conversion efficiency ratio of 0.267x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-9.79 Million) by net assets ($-36.63 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Atara Biotherapeutics Inc - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Atara Biotherapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Atara Biotherapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Atara Biotherapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Arzum Elektrikli Ev Aletleri Sanayi ve Ticaret AS
IS:ARZUM
|
7.089x |
|
Moulinvest
PA:ALMOU
|
0.113x |
|
Drb Holding
KO:004840
|
0.042x |
|
Oriental Aromatics Limited
NSE:OAL
|
-0.046x |
|
X4 PHARMACEUTIC. DL-001
F:48Q
|
N/A |
|
Chuwa Wool Industry Co Taiwan Ltd
TW:1439
|
0.032x |
|
TS Corp Preference Shares
KO:001795
|
0.061x |
|
YLAB Corporation
KQ:432430
|
-0.149x |
Annual Cash Flow Conversion Efficiency for Atara Biotherapeutics Inc (2012–2024)
The table below shows the annual cash flow conversion efficiency of Atara Biotherapeutics Inc from 2012 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-97.28 Million | $-68.72 Million | 0.706x | -63.68% |
| 2023-12-31 | $-99.23 Million | $-192.98 Million | 1.945x | +191.07% |
| 2022-12-31 | $126.64 Million | $-270.43 Million | -2.135x | -170.76% |
| 2021-12-31 | $279.61 Million | $-220.52 Million | -0.789x | -101.72% |
| 2020-12-31 | $462.34 Million | $-180.76 Million | -0.391x | +51.75% |
| 2019-12-31 | $290.78 Million | $-235.63 Million | -0.810x | -52.74% |
| 2018-12-31 | $338.86 Million | $-179.77 Million | -0.531x | -7.84% |
| 2017-12-31 | $177.86 Million | $-87.50 Million | -0.492x | -107.96% |
| 2016-12-31 | $253.74 Million | $-60.02 Million | -0.237x | -100.62% |
| 2015-12-31 | $315.10 Million | $-37.16 Million | -0.118x | +26.83% |
| 2014-12-31 | $103.18 Million | $-16.63 Million | -0.161x | -129.76% |
| 2013-12-31 | $-11.02 Million | $-5.97 Million | 0.542x | -18.45% |
| 2012-12-31 | $-3.73 Million | $-2.48 Million | 0.664x | -- |